US protection ending in 2029: Heart and blood vessels
As of the edition of 20 October 2026, 29 drugs have US protection that ends in 2029 in heart and blood vessels; 19 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
29 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Abacavir | Ends 2029 (patent) | Marketed | GSK | 0 | |
| Afatinib | Ends 2029 (patent) | Marketed | Boehringer Ingelheim | EGFR | 1 |
| Atazanavir | Ends 2029 (patent) | Marketed | Bristol Myers Squibb | 0 | |
| Atezolizumab | Ends 2029 (orphan exclusivity) | Marketed | Roche | CD274 | 1 |
| Avelumab | Ends 2029 (computed from the first US licence) | Marketed | Merck KGaA | CD274 | 1 |
| Azacitidine | Ends 2029 (exclusivity) | Marketed | Bristol Myers Squibb | DNMT1, DNMT3A | 4 |
| Bendamustine | Ends 2029 (patent) | Marketed | Teva | 0 | |
| Brentuximab vedotin | Ends 2029 (orphan exclusivity) | Marketed | Pfizer | TNFRSF8, TUBB, TUBB1 | 10 |
| Budesonide | Ends 2029 (exclusivity) | Marketed | NR3C1 | 5 | |
| Canagliflozin anhydrous | Ends 2029 (patent) | Marketed | Johnson & Johnson | SLC5A2 | 2 |
| Crisaborole | Ends 2029 (patent) | Marketed | Pfizer | PDE4A, PDE4B, PDE4C | 0 |
| Crizotinib | Ends 2029 (patent) | Marketed | Pfizer | ALK, MET, ROS1 | 2 |
| Dapagliflozin | Ends 2029 (patent) | Marketed | AstraZeneca | SLC5A2 | 2 |
| Edaravone | Ends 2029 (exclusivity) | Marketed | Shionogi | 0 | |
| Emicizumab | Ends 2029 (computed from the first US licence) | Marketed | Roche | F10, F9 | 2 |
| Ferric derisomaltose | Ends 2029 (patent) | Marketed | Pharmacosmos | TF | 2 |
| Florbetaben | Ends 2029 (patent) | Marketed | Lantheus Biosciences | 0 | |
| Flurpiridaz | Ends 2029 (exclusivity) | Marketed | GE Healthcare | 0 | |
| Guselkumab | Ends 2029 (computed from the first US licence) | Marketed | Johnson & Johnson | IL23A | 1 |
| Ixazomib citrate | Ends 2029 (patent) | Marketed | Takeda | PSMB5 | 0 |
| Landiolol | Ends 2029 (exclusivity) | Marketed | Aop Health | ADRB1 | 1 |
| Lapatinib | Ends 2029 (patent) | Marketed | Novartis | EGFR | 2 |
| Nitric oxide | Ends 2029 (patent) | Marketed | Byk-Mallinckrodt CIL | GUCY1B1, GUCY1B2 | 4 |
| Phenobarbital | Ends 2029 (exclusivity) | Marketed | SUN Pharmaceutical Industries | 0 | |
| Ruxolitinib | Ends 2029 (exclusivity) | Marketed | JAK1, JAK2 | 4 | |
| Sarilumab | Ends 2029 (computed from the first US licence) | Marketed | Sanofi | IL6R | 1 |
| Suvorexant | Ends 2029 (patent) | Marketed | Merck & Co. | HCRTR1, HCRTR2 | 2 |
| Terlipressin | Ends 2029 (exclusivity) | Marketed | Byk-Mallinckrodt CIL | AVPR1A, AVPR1B, AVPR2 | 3 |
| Varicella zoster virus envelope glycoprotein e | Ends 2029 (computed from the first US licence) | Marketed | GSK | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2029 in heart and blood vessels
In the product19 of these 29 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.